MichaelE.RyttingMD

Associate Professor, Pediatrics and Leukemia

Dr. Rytting is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
4845 Alameda Ave
El Paso, TX 79905
Phone+1 915-215-5700

Fax+1 915-215-8872

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Pediatric Hematology/Oncology, 1994 - 1997
University of Texas Health Science Center at HoustonResidency, Internal Medicine, 1990 - 1994
University of Michigan Medical SchoolClass of 1990

PubMed

7 citations
Venetoclax and Decitabine in Pediatric Refractory T-cell Lymphoblastic Lymphoma.
Muhammad Baig, Michael Rytting, Michael Roth, Ajaykumar C. Morani, Cesar Nunez
Journal of Pediatric Hematology/oncology. 2021-10-01
3 citations
Coincidental Expression of Classic Hodgkin Lymphoma and Neurofibromatosis Type I and Literature Review.
Trevor B. Cabrera, Wei Wang, Sireesha Yedururi, John M. Slopis, Raphael E Steiner
Journal of Pediatric Hematology/oncology. 2021-05-01
84 citations
Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia.
Francesco Paolo Tambaro, Harjeet Singh, Emily Jones, Michael Rytting, Kris M. Mahadeo
Leukemia. 2021-04-08

Abstracts/Posters

Prognostic Significance of IKZF1, PAX5, and CDKN2A Deletions in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Hyper-CVAD/MA ...
Michael E. Rytting, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens
Michael E. Rytting, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia
Michael E. Rytting, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II TrialClinically Relevant Abstract
Michael E. Rytting, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pt...
Michael E. Rytting, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Use of Pegylated Interferon in Six Pediatric Patients with Myeloproliferative Neoplasms
Michael E. Rytting, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all